Bruker (NASDAQ:BRKR) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Bruker (NASDAQ:BRKR) announced its quarterly earnings data on Tuesday. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11, Zacks reports. The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm’s revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 EPS. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker’s conference call:

• Positive Sentiment: Bruker returned to organic revenue growth in Q2, with revenue up 5.2% year over year and organic bookings growth of 10%; biopharma bookings rose more than 20%, while semiconductor metrology and energy research orders grew more than 50%.
• Positive Sentiment: Cost reductions, favorable mix and volume drove a 510-basis-point increase in non-GAAP operating margin to 14.1%, while non-GAAP EPS rose 53% to $0.49. The company remains on track for $140 million in annualized 2026 savings and expects an additional $20 million of savings from its new operating structure in 2027.
• Positive Sentiment: Management reiterated its 2026 outlook, including 1%-2% organic revenue growth, 250-300 basis points of operating-margin expansion and non-GAAP EPS of $2.10-$2.15, representing 15%-17% growth. Executives also expect further margin expansion and double-digit EPS growth in 2027.
• Negative Sentiment: U.S. academic and government demand remained weak, contributing to a more than $15 million year-over-year revenue decline in that market during Q2, while Asia-Pacific revenue fell by low double digits. A $135 million non-cash goodwill impairment tied to the loss-making automation and spatial biology businesses resulted in a GAAP diluted loss of $0.41 per share.
• Neutral Sentiment: About $20 million of semiconductor revenue is shifting from Q3 into Q4 due to customer delivery requirements, leading management to expect Q3 organic revenue to be roughly flat to slightly up and sequentially lower margins and EPS. The company expects a significantly stronger Q4, supported by semiconductor deliveries, an ultra-high-field system and improved volume and mix.

Bruker Price Performance

NASDAQ BRKR traded up $1.65 on Wednesday, reaching $51.95. The company had a trading volume of 2,606,989 shares, compared to its average volume of 2,415,276. The firm’s 50 day moving average price is $58.59 and its 200 day moving average price is $46.71. Bruker has a 12 month low of $28.53 and a 12 month high of $65.30. The stock has a market capitalization of $7.91 billion, a PE ratio of -215.81, a price-to-earnings-growth ratio of 2.06 and a beta of 1.28. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were given a dividend of $0.05 per share. The ex-dividend date was Monday, June 22nd. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker’s payout ratio is -83.33%.

Key Stories Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported second-quarter adjusted earnings of $0.49 per share, well above the $0.38 analyst consensus and up from $0.32 a year earlier. The earnings beat and stronger margins provide support for the stock. Bruker Q2 Earnings Beat Estimates
• Positive Sentiment: Management maintained fiscal 2026 adjusted EPS guidance of $2.10 to $2.15, broadly in line with the $2.12 consensus. The earnings outlook was not reduced despite the revenue guidance adjustment. Bruker Corporation Earnings Call Highlights Margin Strength
• Neutral Sentiment: Second-quarter revenue increased 5.2% year over year to $838.5 million, but missed the $853.6 million analyst estimate. The mixed result helps explain investor caution even as earnings exceeded expectations. Bruker Q2 Earnings Snapshot
• Negative Sentiment: Bruker lowered its fiscal 2026 reported revenue guidance to approximately $3.54 billion-$3.57 billion from $3.57 billion-$3.60 billion. Management attributed the change primarily to foreign exchange and tax assumptions, but investors remain focused on slower growth in the company’s core markets. Weak Growth in Its Primary Market Continues to Weigh Heavily on Bruker Shares
• Negative Sentiment: About $20 million of revenue is expected to shift from the third quarter into the fourth quarter because of semiconductor-customer delivery timing, creating a weaker near-term revenue profile. Bruker also recorded a $134.9 million non-cash goodwill impairment, resulting in a GAAP loss for the quarter. Bruker Revenue Outlook and Q3 Timing Shift

Institutional Trading of Bruker

A number of hedge funds and other institutional investors have recently modified their holdings of BRKR. Allworth Financial LP lifted its stake in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares in the last quarter. Federated Hermes Inc. raised its position in Bruker by 6.7% in the fourth quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock worth $284,000 after acquiring an additional 380 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Bruker in the 4th quarter valued at $26,000. Finally, UMB Bank n.a. boosted its holdings in shares of Bruker by 57.9% during the fourth quarter. UMB Bank n.a. now owns 1,571 shares of the medical research company’s stock worth $74,000 after purchasing an additional 576 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BRKR shares. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. UBS Group set a $60.00 price target on shares of Bruker in a research note on Wednesday, June 24th. Leerink Partners boosted their target price on Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Finally, JPMorgan Chase & Co. lifted their price objective on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Bruker currently has a consensus rating of “Hold” and a consensus target price of $57.14.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.